跳至主要内容
临床试验/NCT02745925
NCT02745925已完成不适用

Mechanism of Decreased Iron Absorption in Obesity: Controlling Adiposity-related Inflammation

Swiss Federal Institute of Technology1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2016年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
40
试验地点
1
主要终点
Fractional iron absorption

研究概览

简要总结

The main iron regulatory protein in the human metabolism is hepcidin. In normal weight, healthy subjects, hepcidin is regulated through the iron status of the body: low iron status results in low hepcidin concentrations, which facilitates dietary iron absorption. In obesity, which is an inflammatory state, hepcidin concentrations are increased and iron absorption is reduced despite low iron stores, leading to iron deficiency over time. Whether lowering the chronic low-grade inflammation during a limited treatment period and thereby lowering hepcidin concentration can improve iron absorption is uncertain.

详细描述

In states of high hepcidin concentration, intestinal iron absorption (through enterocytes) and recycling of iron (through macrophages) is reduced. The extent to which non-heme iron is absorbed from the diet is influenced by the composition of the diet. Ascorbic acid is a potent enhancer of non-heme iron absorption. It's mechanism of action is luminal reduction of dietary ferric iron (Fe3+) to more soluble ferrous iron (Fe2+). A study in the inestigator's laboratory showed that the enhancing effect of ascorbic acid on non-heme iron absorption is reduced in overweight and obese individuals. Possible explanations for this fact are the different sites of action of ascorbic acid and serum hepcidin on the enterocytes in dietary iron absorption. Increased hepcidin reduces iron efflux into the circulation at the basolateral membrane of the enterocyte. Therefore the improved iron transport into enterocytes through ascorbic acid at the luminal side (via the divalent metal transporter (DMT)-1), by reducing Fe3+ to Fe2+ seems to be less successful. To improve iron absorption in obese subjects, an intervention at the basolateral membrane of the enterocyte would be needed.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • normal-weight (BMI18.5-24.9kg/m2) or obesity (BMI 29-40kg/m2)
  • pre-menopausal
  • no chronic illness and no significant medical conditions that could influence iron or inflammatory status other than obesity
  • no-smoking

排除标准

  • Diagnosed chronic disease or gastrointestinal disorders
  • Metabolic disorders (e.g. diabetes)
  • Regular use of medication (except oral contraceptives)
  • Subject on a weight loss diet or planning to start a weight loss diet during the duration of the study
  • Pregnancy or lactation

研究组 & 干预措施

normal-weight

Experimental

normal-weight women

干预措施: Ibuprofen (Drug)

obesity

Experimental

obese women

干预措施: Ibuprofen (Drug)

结局指标

主要结局

Fractional iron absorption

时间窗: Days 15 and 45

The fractional iron absorption from four test meals will be calculated based on the shift of the iron isotopic ratios in the collected blood samples 14 days after administration of the isotopically labeled meals. Calculation of fractional iron absorption will take into account the principles of isotope dilution and the fact that iron isotopic labels are not mono-isotopic. The investigators assumed iron incorporation into erythrocytes to be constant. Blood volume, needed for the calculation of fractional iron absorption will be estimated based on available data on blood volume estimations in obese women.

次要结局

  • alpha-1-acid-glycoprotein(Days 1, 15, 30, 45)
  • Plasma ferritin(Days 1, 15, 30, 45)
  • Hemoglobin(Days 1, 15, 30, 45)
  • Hepcidin(Days 1, 15, 30, 45)
  • c-reactive protein(Days 1, 15, 30, 45)
  • interleukin-6(Days 1, 15, 30, 45)
  • Transferrin receptor(Days 1, 15, 30, 45)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Isabelle Herter-Aeberli

Dr.

Swiss Federal Institute of Technology

研究点 (1)

Loading locations...

相似试验